Long-term effects of corticosteroid nasal spray on nasal inflammatory cells in patients with perennial allergic rhinitis
Article first published online: 24 DEC 2001
Clinical & Experimental Allergy
Volume 29, Issue 10, pages 1356–1366, October 1999
How to Cite
Holm, Godthelp, Fokkens, M. Severijnen, Mulder, Vroom and Rijntjes (1999), Long-term effects of corticosteroid nasal spray on nasal inflammatory cells in patients with perennial allergic rhinitis. Clinical & Experimental Allergy, 29: 1356–1366. doi: 10.1046/j.1365-2222.1999.00665.x
- Issue published online: 24 DEC 2001
- Article first published online: 24 DEC 2001
- Langerhans' cells;
- mast cells;
- nasal mucosa;
- T lymphocytes
The effect of long-term topical nasal corticosteroid therapy on nasal inflammatory cells is unclear.
To investigate the long-term effect of fluticasone propionate aqueous nasal spray (FPANS) on nasal mucosal inflammatory cells and efficacy in a 1-year study in patients with perennial allergic rhinitis.
In a 1-year, double-blind, placebo-controlled study of duration we investigated the influence of a topical corticosteroid (FPANS), on Langerhans' cells (CD1a+ cells), T cells, mast cells, eosinophils and macrophages in nasal mucosa in 42 patients with perennial allergic rhinitis. Efficacy was evaluated by nasal symptom score.
The FPANS group experienced significantly less sneezing and nasal itching compared with the placebo group. The total symptom score in the FPANS group declined significantly in comparison with baseline (P = 0.007) and placebo group (P = 0.009). After 1 year of active treatment, a significant decrease was seen in the epithelium in numbers of Langerhans' cells, CD3+, CD4+, CD8+ cells, mast cells and eosinophils. In the lamina propria, there was a significant decrease in eosinophils.
These findings show that FPANS treatment results in a decrease of nasal inflammatory cells. Furthermore, the efficacy of FPANS improves after prolonged treatment.